Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+1.54M
-
Total reported value, excl. options
-
$339M
-
Value change
-
+$13.1M
-
Put/Call ratio
-
0.58
-
Number of buys
-
77
-
Number of sells
-
-48
-
Price
-
$10.76
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2023
156 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2023.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
.
Largest 10 shareholders include BlackRock Inc. (3.39M shares), VANGUARD GROUP INC (3.26M shares), BAKER BROS. ADVISORS LP (2.8M shares), Rubric Capital Management LP (2.78M shares), STATE STREET CORP (1.8M shares), PICTET ASSET MANAGEMENT SA (1.44M shares), MORGAN STANLEY (1.33M shares), HHLR ADVISORS, LTD. (1.02M shares), ArrowMark Colorado Holdings LLC (887K shares), and Hudson Bay Capital Management LP (860K shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.